REMEGEN(SH:688331) Zheng Quan Zhi Xing·2025-04-02 13:51Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 Second Extraordinary General Meeting of Rongchang Biopharmaceuticals (Yantai) Co., Ltd. comply with relevant laws, regulations, and the company's articles of association [1][2][3][4][8] Group 1: Meeting Procedures - The meeting was convened on April 2, 2025, as per the notice published [3][4] - The meeting took place at the company's designated location and was presided over by the chairman [3][4] Group 2: Attendance and Qualifications - A total of 101 participants attended the meeting, representing 192,803,132 shares, which is 35.4201% of the total voting shares [4][5] - The qualifications of the attendees, including A-share and H-share holders, were verified and found to be compliant with legal requirements [5][6] Group 3: Voting Procedures and Results - The voting was conducted through a named voting method, with results verified by representatives and legal counsel [6][8] - The resolutions were passed with 217,911,121 votes in favor, representing a significant majority of the voting shares [6][7][8]